A Case of Hemolytic Uremic Syndrome Following Mitomycin C Treated with Long Intensive Plasmapheresis.
- Author:
Dong Ho SHIN
1
;
Mi Jung LEE
;
Hyun sung PARK
;
Jwa kyung KIM
;
Jung Tak PARK
;
Tae Ik CHANG
;
Tae Hyun YOO
;
Shin Wook KANG
;
Kyu Hun CHOI
Author Information
1. Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea. yoosy0316@yuhs.ac
- Publication Type:Case Report
- Keywords:
Hemolytic-Uremic syndrome;
Mitomycin;
Plasmapheresis
- MeSH:
Acute Kidney Injury;
Anemia, Hemolytic;
Cyclosporine;
Diarrhea;
Hemolytic-Uremic Syndrome;
Humans;
Mitomycin;
Plasmapheresis;
Quinine;
Renal Insufficiency, Chronic;
Thrombocytopenia;
Ticlopidine;
Uterine Cervical Neoplasms
- From:Korean Journal of Nephrology
2010;29(5):662-666
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
HUS (Hemolytic Uremic Syndrome) is characterized by acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia. In classical HUS, hemorrhagic diarrhea precedes. It is frequently associated with E. Coli O157:H7. Less frequently, HUS may also develop after various treatments such as mitomycin C, cyclosporine, quinine, and ticlopidine. Plasmapheresis is effective in most of classical HUS, which induces a complete remission in most patients with classical HUS. However, this treatment is ineffective in HUS associated with mitomycin C. Although Plasmapheresis is effective on hematologic abnormality in this atypical HUS, chronic renal insufficiency frequently persists as a sequella in HUS associated with mitomycin C. We here report on one patient who developed HUS following mitomycin C therapy due to cervix cancer. The patient was treated with intensive and prolonged plasmapheresis. There was a complete hematologic improvement and steady improvement in renal function.
